Clinical Trials Directory
We are doing this study to evaluate an experimental technology called the Reprieve Decongestion Management System (the study device) for heart failure patients with fluid overload. The study device is designed to help people with heart failure feel better by removing extra fluid from their body quickly. The device is programmed to deliver an appropriate amount of medication at the right time to help people shed extra fluid through urination. We want to know if this device works better than the standard treatment. The standard treatment is to prescribe diuretics (medication to increase urination) at a specified dose and dosage schedule.
We are doing this study to examine genetic changes in your tumor that may contribute to resistance to immunotherapy. With this information, we hope to be able to identify new treatment methods as well as improve our ability to identify patients more likely to respond to immunotherapy.
After the screening, the study will last up to one year and has two parts. People in the study will be randomly placed into two groups. In Part A, one group will get the study medicine, and the other group will get a placebo, which looks like the medicine but does not do anything. In Part B, everyone will get the study medicine. The medicine or placebo will be given through a tube into a vein in the arm. During the study, everyone will have checkups, give blood samples, have kidney tissue samples taken (called biopsies), and answer questions about how they feel.
We are doing this study to find the most effective, safe dose of an experimental drug called FG-3246 (the study drug) that is being developed for people with metastatic castration-resistant prostate cancer. We want to know if it is able to shrink the size of tumors and delay the progression of the disease.
We are doing this study to find out if an experimental drug called LY4337713 (the study drug) is a safe and effective option for people who have FAP-positive solid tumors. The study drug is a type of radiotherapy that is intended to target and attach only to FAP. The goal of targeted radiotherapy is to provide selective delivery of radiation doses that can destroy tumor cells.
We are doing this study to understand more about biomarkers (a part of your body) and how they can be used to better diagnose infection. To learn more, please contact us at DukeMESSIStudy@Duke.edu or at 919-452-1605. Estamos haciendo este estudio para entender más sobre biomarcadores (que son parte de su cuerpo) y cómo pueden ser usados estos para diagnosticar infecciones de una mejor manera. Para mayor información, por favor contáctenos al correo DukeMESSIStudy@Duke.edu o al número 919-452-1605.